Massive Bio and GELL Announce Partnership to Advance AI‑Powered Oncology Research in Latin America and the U.S. The collaboration brings together Massive Bio’s artificial‑intelligence platform for trial matching and patient navigation with the Latin American Study Group on Lymphoproliferative Disorders (GELL), a network of more than 20 countries that shapes lymphoma research and education across the region.
A cross‑continental AI alliance
Massive Bio, a Florida‑based AI specialist, and GELL, the premier scientific consortium for hematologic malignancies in Latin America, signed a strategic agreement on July 27, 2026. The deal is not a simple sponsorship; it creates a joint engine for clinical‑trial recruitment, physician education, and AI literacy. By embedding Massive Bio’s real world data analytics into GELL’s investigator network, the partnership aims to accelerate enrollment in precision‑oncology studies and to demystify AI‑driven decision support for oncologists and hematologists.
Why AI matters for oncology today
Artificial intelligence is shifting from experimental labs to bedside tools. Gartner predicts that by 2027, 75 % of healthcare organizations will use AI to improve clinical decision‑making, up from 30 % in 2023. In oncology, AI can sift through genomic, imaging, and electronic health‑record data to identify patients who meet complex eligibility criteria for targeted therapies. Massive Bio’s platform automates this matching process, reducing manual chart reviews by up to 60 % in pilot programs, according to internal benchmarks.
For GELL’s members, many of whom operate in resource‑constrained settings, AI offers a scalable way to connect patients with trials that would otherwise be invisible. The partnership’s educational component—webinars, regional workshops, and joint scientific forums—targets the knowledge gap that still exists in many Latin American hospitals about AI’s practical applications.
Competitive landscape: where does this partnership sit?
The AI‑oncology space is crowded. Companies such as Tempus, IBM Watson Health, and Flatiron Health provide data‑centric platforms that combine clinical trial matching with analytics. What differentiates Massive Bio’s approach is its focus on a “real‑world” data feed that continuously ingests de‑identified patient outcomes, feeding back efficacy signals to trial sponsors.
GELL’s regional reach adds a unique moat. While most AI vendors concentrate on North America or Europe, GELL offers direct access to more than 200 investigators across Brazil, Mexico, Argentina, and smaller markets like Costa Rica and Uruguay. This geographic breadth is a rare asset for AI firms seeking to expand beyond the U.S. market.
Implications for enterprise healthcare
For large health systems and pharma companies, the collaboration signals a template for scaling AI adoption through existing scientific societies. By leveraging GELL’s credibility, Massive Bio can bypass the lengthy trust‑building phase that typically stalls AI projects. Enterprises that already use cloud AI services from Google, Amazon, or Microsoft will find the Massive Bio platform compatible with major data‑lake architectures, easing integration.
The partnership also underscores a shift toward “AI‑enabled networks” where data, expertise, and trial infrastructure are co‑owned. Enterprises that invest early in such ecosystems may gain faster patient recruitment, lower trial costs, and stronger compliance with emerging data‑privacy regulations in Latin America, such as Brazil’s LGPD.
How the alliance will operate on the ground
- Joint educational programs – Quarterly webinars featuring case studies of AI‑assisted trial enrollment, co‑hosted by Massive Bio data scientists and GELL’s clinical leaders.
- Multicenter research pilots – Three pilot studies launching in 2027 that will use the AI platform to identify eligible lymphoma patients across 15 hospitals in Brazil and Mexico.
- AI literacy initiatives – Certification courses for physicians that cover algorithmic bias, data governance, and practical workflow integration.
These activities are designed to produce measurable outcomes: a 25 % increase in trial enrollment rates for participating sites and a 30 % rise in AI‑related CME credits awarded to GELL members within the first year.
Industry perspective
Analysts at Forrester note that “AI adoption in oncology will be the litmus test for broader AI acceptance in clinical practice.” The Massive Bio–GELL partnership aligns with that view, offering a concrete use case that blends technology with a trusted scientific community. If the pilots deliver on their enrollment targets, they could set a benchmark for other specialty societies—oncology, cardiology, neurology—to replicate similar AI collaborations.
Market Landscape
The global AI‑in‑healthcare market is projected by IDC to reach $188 billion by 2028, driven largely by oncology and radiology use cases. Latin America, however, lags behind North America in AI penetration, with Statista reporting that only 12 % of hospitals in the region have deployed AI tools as of 2025. Partnerships like the one between Massive Bio and GELL aim to close this gap by providing both technology and the educational scaffolding needed for adoption.
Regulatory environments are also evolving. The U.S. FDA’s Digital Health Center of Excellence has released guidance on AI/ML‑based medical devices, while Brazil’s ANVISA is drafting similar frameworks. Enterprises that can demonstrate responsible AI use—through transparent models, bias mitigation, and post‑market surveillance—will be better positioned to navigate these emerging rules.
Top Insights
- The Massive Bio–GELL partnership creates the first AI‑focused clinical‑trial network that spans both North and South America, offering a scalable model for other therapeutic areas.
- AI‑driven trial matching can cut patient screening time by up to 60 %, accelerating drug development timelines and reducing costs for sponsors.
- Educational initiatives embedded in the deal address the biggest barrier to AI adoption—physician trust—by delivering hands‑on training and certification.
- By aligning with a respected scientific society, Massive Bio gains immediate credibility, shortening the sales cycle for enterprise healthcare customers.
- The collaboration highlights a broader industry trend: AI platforms are moving from isolated tools to ecosystem partners that co‑create value with clinical networks.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
